Search Results

. She was looking to identify ways to address the discordance between an extrapolation of the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) combined with the SEER database of annual incidence of acute myeloid leukemia (AML) in patients

outcomes among patients with acute myeloid leukemia or myelodysplasia receiving allogeneic hematopoietic cell transplantation . J Clin Oncol 2007 ; 25 : 4246 – 4254 . 10. Sorror ML Storer B Sandmaier BM . Allogeneic hematopoietic cell

after I finished speaking with the daughter (let’s call her Beth) of a patient who was starting an oral anticancer drug (venetoclax) for acute myeloid leukemia. I explained to Beth that although she was “told” the treatment would start next week, it all

data and 229 were available for analysis ( Figure 1 ). Median age was 77 years (range, 24–99 years), with 35% female and 58% born outside Australia. Other demographics are described in Table 1 . Acute myeloid leukemia was the most frequent diagnosis

NCCN Guidelines. Presentations included treatment updates and patient case studies on: Acute Lymphoblastic Leukemia Acute Myeloid Leukemia Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Chronic Myeloid Leukemia Diffuse Large B

as Vice President of Community and Support for an online virtual world. He holds a bachelor's degree in Computer and Information Sciences from the University of Massachusetts. In November 2010, Mr. Greene was diagnosed with acute myeloid leukemia

acute myeloid leukemia (AML) evolution. It should NCCN Guidelines Insights : Myelodysplastic Syndromes, Version 2.2015 Version 2.2015 © National Comprehensive Cancer Network, Inc. 2015, All rights reserved. The NCCN Guidelines® and this

– 43 , 46 , 51 , 56 examined characteristics associated with functional improvement. Three articles 34 , 51 , 56 reporting results of a study of acute myeloid leukemia found that younger age was associated with greater improvement in timed chair

. Additional indications for filgrastim and filgrastim-sndz include treatment for patients with acute myeloid leukemia (AML) receiving induction or consolidation chemotherapy, patients with cancer receiving bone marrow transplant, patients undergoing peripheral

developing acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) in patients treated with MGFs. In an analysis of data from the SEER-Medicare linked files, Hershman et al 28 observed a doubling of the risk of subsequent AML or MDS from 0.7% to 1